Hologic and Bayer are entering into an international partnership to deliver contrast-enhanced mammography (CEM) to improve breast cancer detection for women in multiple countries across the European, Canadian, and Asia Pacific regions.
The partnership brings together Hologic's mammography gantries and Bayer's CEM-approved injection systems to allow for contrast media administration during a mammography exam. With the new agreement, the companies want to support radiologists and the needs of their teams by providing a comprehensive product package and hands-on training.
Through this, the companies say they will help increase access to additional breast imaging technology that may also improve health outcomes for patients. They also noted increased interest in CEM over the past several years for diagnostic breast imaging.
